163 related articles for article (PubMed ID: 21610004)
1. The superiority of the time-to-event continual reassessment method to the rolling six design in pediatric oncology Phase I trials.
Zhao L; Lee J; Mody R; Braun TM
Clin Trials; 2011 Aug; 8(4):361-9. PubMed ID: 21610004
[TBL] [Abstract][Full Text] [Related]
2. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
Normolle D; Lawrence T
J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
[TBL] [Abstract][Full Text] [Related]
3. Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.
Polley MY
Stat Med; 2011 Jul; 30(17):2130-43. PubMed ID: 21590790
[TBL] [Abstract][Full Text] [Related]
4. A simulation-based comparison of the traditional method, Rolling-6 design and a frequentist version of the continual reassessment method with special attention to trial duration in pediatric Phase I oncology trials.
Onar-Thomas A; Xiong Z
Contemp Clin Trials; 2010 May; 31(3):259-70. PubMed ID: 20298812
[TBL] [Abstract][Full Text] [Related]
5. A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method.
North B; Kocher HM; Sasieni P
BMC Cancer; 2019 Jun; 19(1):632. PubMed ID: 31242873
[TBL] [Abstract][Full Text] [Related]
6. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
James GD; Symeonides S; Marshall J; Young J; Clack G
BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
[TBL] [Abstract][Full Text] [Related]
7. Rolling continual reassessment method with overdose control: An efficient and safe dose escalation design.
Zhu J; Sabanés Bové D; Liao Z; Beyer U; Yung G; Sarkar S
Contemp Clin Trials; 2021 Aug; 107():106436. PubMed ID: 34000410
[TBL] [Abstract][Full Text] [Related]
8. Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples.
van Werkhoven E; Hinsley S; Frangou E; Holmes J; de Haan R; Hawkins M; Brown S; Love SB
BMC Med Res Methodol; 2020 Jun; 20(1):162. PubMed ID: 32571298
[TBL] [Abstract][Full Text] [Related]
9. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.
Yuan Y; Lin R; Li D; Nie L; Warren KE
Clin Cancer Res; 2018 Oct; 24(20):4921-4930. PubMed ID: 29769209
[TBL] [Abstract][Full Text] [Related]
10. Two-stage subgroup-specific time-to-event (2S-Sub-TITE): An adaptive two-stage time-to-toxicity design for subgroup-specific dose finding in phase I oncology trials.
McGovern A; Chapple AG; Ma C
Pharm Stat; 2022 Nov; 21(6):1138-1148. PubMed ID: 35560864
[TBL] [Abstract][Full Text] [Related]
11. Dose-finding designs in pediatric phase I clinical trials: comparison by simulations in a realistic timeline framework.
Doussau A; Asselain B; Le Deley MC; Geoerger B; Doz F; Vassal G; Paoletti X
Contemp Clin Trials; 2012 Jul; 33(4):657-65. PubMed ID: 22521954
[TBL] [Abstract][Full Text] [Related]
12. Incorporating patient-reported outcomes in dose-finding clinical trials with continuous patient enrollment.
Andrillon A; Biard L; Lee SM
J Biopharm Stat; 2023 Jul; ():1-12. PubMed ID: 37496233
[TBL] [Abstract][Full Text] [Related]
13. Using the time-to-event continual reassessment method in the presence of partial orders.
Wages NA; Conaway MR; O'Quigley J
Stat Med; 2013 Jan; 32(1):131-41. PubMed ID: 22806898
[TBL] [Abstract][Full Text] [Related]
14. Monitoring late-onset toxicities in phase I trials using predicted risks.
Bekele BN; Ji Y; Shen Y; Thall PF
Biostatistics; 2008 Jul; 9(3):442-57. PubMed ID: 18084008
[TBL] [Abstract][Full Text] [Related]
15. Continual reassessment method vs. traditional empirically based design: modifications motivated by Phase I trials in pediatric oncology by the Pediatric Brain Tumor Consortium.
Onar A; Kocak M; Boyett JM
J Biopharm Stat; 2009; 19(3):437-55. PubMed ID: 19384687
[TBL] [Abstract][Full Text] [Related]
16. Practical modifications of the continual reassessment method for phase I cancer clinical trials.
Faries D
J Biopharm Stat; 1994 Jul; 4(2):147-64. PubMed ID: 7951271
[TBL] [Abstract][Full Text] [Related]
17. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies.
Iasonos A; Wilton AS; Riedel ER; Seshan VE; Spriggs DR
Clin Trials; 2008; 5(5):465-77. PubMed ID: 18827039
[TBL] [Abstract][Full Text] [Related]
19. Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial.
Huang B; Kuan PF
Biom J; 2014 Nov; 56(6):933-46. PubMed ID: 24895140
[TBL] [Abstract][Full Text] [Related]
20. Determining a maximum tolerated cumulative dose: dose reassignment within the TITE-CRM.
Braun TM; Levine JE; Ferrara JL
Control Clin Trials; 2003 Dec; 24(6):669-81. PubMed ID: 14662273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
